Current Management and Controversies Surrounding Andropause

Abrar H Mian; David Y Yang; Tobias S Kohler

doi:10.1016/j.ucl.2022.07.003

Current Management and Controversies Surrounding Andropause

Urol Clin North Am. 2022 Nov;49(4):583-592. doi: 10.1016/j.ucl.2022.07.003. Epub 2022 Oct 7.

Authors

Abrar H Mian¹, David Y Yang², Tobias S Kohler³

Affiliations

¹ Midwestern University, Chicago College of Osteopathic Medicine, 555 31st Street, Downers Grove, IL 60515, USA. Electronic address: https://twitter.com/AbrarMian8.
² Department of Urology, Emory University, 100 Woodruff Circle, Atlanta, GA 30322, USA. Electronic address: https://twitter.com/YangUrology.
³ Department of Urology, Mayo Clinic: Rochester, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: kohler.tobias@mayo.edu.

PMID: 36309415
DOI: 10.1016/j.ucl.2022.07.003

Abstract

Andropause is a condition surrounded by controversies, whether it be through its diagnosis or management. As we learn more about the pathophysiology of hypogonadism, our perspectives on the risks and benefits of testosterone therapy have shifted. We attempt to discuss the most modern and relevant points of controversy currently affecting the field. Throughout this review, we discuss the art of diagnosing hypogonadism as well as the association or lack thereof between testosterone replacement therapy and cardiovascular disease, prostate cancer, thrombosis, antiaging effects, exogenous steroid abuse, and diabetes mellitus.

Keywords: Andropause; Hypogonadism; TRT; Testosterone.

Publication types

Review

MeSH terms

Andropause* / physiology
Hormone Replacement Therapy
Humans
Hypogonadism* / diagnosis
Hypogonadism* / drug therapy
Male
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / drug therapy
Testosterone / therapeutic use

Substances

Testosterone